Class Action Lawsuit Filed Against Pacira BioSciences, Inc.: What Does It Mean for Investors and the World?
On March 1, 2025, The Schall Law Firm announced that it had filed a class action lawsuit against Pacira BioSciences, Inc. (Pacira or the Company) (NASDAQ: PCRX) in the United States District Court for the Southern District of New York. The lawsuit alleges that the Company violated the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, specifically Sections 10(b) and 20(a).
Class Action Lawsuit Details
The complaint asserts that Pacira misled investors during the Class Period, which spans from August 2, 2023, to August 8, 2024. The lawsuit alleges that the Company made false and misleading statements regarding the commercial prospects of its EXPAREL product, its financial performance, and its regulatory compliance.
According to the complaint, Pacira failed to disclose that: (1) EXPAREL’s market acceptance had decreased, (2) the Company was experiencing significant price erosion, (3) Pacira’s financial results would be negatively impacted, and (4) the Company was not in compliance with certain regulatory requirements.
Impact on Investors
Investors who purchased Pacira’s securities during the Class Period may be eligible to recover their losses. The Schall Law Firm urges investors to contact the firm before March 14, 2025, to discuss their legal rights and potential remedies. The lawsuit seeks to recover damages on behalf of all affected investors.
Impact on the World
The class action lawsuit against Pacira BioSciences could have far-reaching implications for the biotech industry and investors as a whole. The allegations of misrepresentation and non-compliance with regulatory requirements could lead to increased scrutiny of other companies in the industry, potentially leading to further lawsuits and regulatory action.
Additionally, the lawsuit could negatively impact Pacira’s reputation, potentially leading to decreased investor confidence and a lower stock price. This could make it more difficult for the Company to raise capital and execute its business strategy.
Conclusion
The class action lawsuit against Pacira BioSciences, Inc. is a significant development for investors, particularly those who purchased the Company’s securities during the Class Period. The allegations of misrepresentation and non-compliance with regulatory requirements could result in significant damages for affected investors. Moreover, the lawsuit could have far-reaching implications for the biotech industry and investors as a whole.
As the legal proceedings unfold, investors are encouraged to stay informed about the case and their potential legal rights. It is essential to work with experienced legal counsel to understand the potential risks and opportunities associated with the situation. By taking a proactive approach, investors can protect their interests and position themselves for potential recovery.
- Pacira BioSciences, Inc. (NASDAQ: PCRX)
- Class Action Lawsuit
- Securities Exchange Act of 1934
- Rule 10b-5
- August 2, 2023, to August 8, 2024
- Allegations of misrepresentation and non-compliance with regulatory requirements
- Potential damages for affected investors
- Far-reaching implications for the biotech industry and investors
